Icosavax — Investor Presentation (November 2021)
33 slides from Icosavax's investor presentation, Nov 18, 2021
Slide 1: Corporate Overview November 2021
Exhibit 99.1 Corporate Overview November 2021
Slide 2: Forward Looking Statements
Forward Looking Statements Statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on the company’s current beliefs and expectations and include, but are not limited to: the company’s expectati
Slide 3: Leadership
Leadership Executive Team Scientific Advisory Board Neil King, Ph.D. Adam Simpson Chair Chief Executive Officer Ralf Clemens, M.D. Doug Holtzman, Ph.D. MPH Chief Scientific Officer Jean-Paul Prieels, Ph.D. Niranjan Kanesa-thasan, M.D. MTMH Chief Medical Officer David Baker, Ph.D. Tom Russo Chief Fin
Slide 4: Novel VLP technology platform to develop vaccines against multiple viral respiratory pathogens
Novel VLP technology platform to develop vaccines against multiple viral respiratory pathogens Recombinant virus-like particle (VLP) platform designed in silico to apply potential advantages of naturally occurring VLPs to other viral indications of interest • VLP technology licensed from the Institu
Slide 5: Recent highlights
Recent highlights Progressing multiple assets in the clinic • Initiated a Phase 1/1b clinical study of IVX-121 RSV vaccine candidate in adults and older adults – Dosing began in September 2021 – Interim top-line data expected in H1 2022 – Planned subsequent development as part of a combination RSV/h
Slide 6: Icosavax pipeline of vaccine candidates against respiratory diseases
Icosavax pipeline of vaccine candidates against respiratory diseases TARGET LEAD CANDIDATE IND-ENABLING NEXT ANTICIPATED COMMERCIAL ANTIGEN PHASE 1 PHASE 2 PHASE 3 INDICATION SELECTION STUDIES MILESTONE RIGHTS Phase 1/1b RSV interim data IVX-121 Monovalent 1H 2022 RSV/hMPV Bivalent* IND RSV/hMPV IVX
Slide 7: Unmet need for vaccines in older adults is increasingly recognized
While vaccinations have historically been focused on infants and young children, the unmet need for vaccines in older adults is increasingly recognized INITIAL TARGET POPULATION Pregnant women 0-6 months 6-60 months Children - adults Older adults Boosted pre-existing Passive Boosted and acquired imm
Slide 8: Icosavax Computationally Designed VLP Platform
Icosavax Computationally Designed VLP Platform Icosavax, Inc. 8
Slide 9: Virus-like particle vaccines allow for multivalent antigen display
Virus-like particle vaccines allow for multivalent antigen display; potential to induce more robust and durable immune responses compared with soluble antigens Soluble antigen VLP-based antigen POTENTIAL FOR: Weaker Activation Signals and Lower Level of Antibodies Stronger signals to activate immune
Slide 10: VLPs have been tried, tested and approved – with several potential benefits
VLPs have been tried, tested and approved – with several potential benefits There are several naturally occurring VLP vaccines on the 2015 market (e.g., HPV, HBV) or in development (e.g., norovirus) Malaria vaccine: Mosquirix (RTS,S) that demonstrate the potential benefits of the approach: 2011 • Ma
Slide 11: Recent SARS-CoV-2 vaccine data support robust magnitude of response with VLP-based vaccines
Recent SARS-CoV-2 vaccine data support the robust magnitude of response that has been achieved utilizing VLP-based vaccines TECHNOLOGY FOLD CHANGE EFFICACY (%) TYPE YA NTS/HCS* ORIGINAL STRAIN* VLP ~5-10 TBD Clinical studies evaluating the VLP approaches have shown the highest fold change over Human
Slide 12: Several limitations of VLP technologies
However, there have been several limitations of VLP technologies NATURAL VLPs/PROTEIN DESIGN FEATURES OF ICOSAVAX ATTRIBUTE ENVELOPED VLPs CARRIERS 2-COMPONENT VLPs Incorporation of complex Limited ✔✔ heterologous antigens Ease of viral clearance/purification Poor ✔✔ Yield/ability to manufacture Poo
Slide 13: The Icosavax VLP platform is a scalable recombinant protein technology
The Icosavax VLP platform is a scalable recombinant protein technology designed for multivalent display of complex viral antigens Component A • Two-component manufacturing – each component uses standard (antigen-specific) recombinant protein production and purification • Component A – Consists of a
Slide 14: RSV/hMPV Bivalent Vaccine Candidate
RSV/hMPV Bivalent Vaccine Candidate Icosavax, Inc. 14
Slide 15: No marketed vaccines for RSV or hMPV, leading viral causes of pneumonia in older adults
There are no marketed vaccines for RSV or hMPV, two of the leading viral causes of pneumonia in older adults Top 5 Pathogens Detected in Adults Hospitalized with • Lower respiratory infection and pneumonia is the leading Community-Acquired Pneumonia (EPIC Study) (Pre-COVID-19) cause of death & hospi
Slide 16: IVX-A12 is designed to target both RSV and hMPV in a single vaccine candidate
Icosavax’s first combination vaccine candidate IVX-A12 is designed to target both RSV and hMPV in a single vaccine candidate IVX-121 IVX-241 RSV and hMPV are related Pneumoviridae and have overlapping seasonal circulation RSV VLP hMPV VLP Both viruses are common with high re-infection rates The goal
Slide 17: High neutralizing antibody titers correlated with reduced risk of infection and disease
High levels of neutralizing antibody titers have been correlated with reduced risk of infection and disease Decreased Risk of ARI due to RSV Correlated with Decreased Risk of hMPV Infection Correlated with High Neutralizing Titers High Neutralizing Titers GEOMETRIC MEAN NAB OR OF ARI^ TITER (GMT LOG
Slide 18: Prefusion RSV-F protein is potentially key to high neutralizing antibody titers
Prefusion RSV-F protein is potentially the key to generating high neutralizing antibody titers Postfusion F protein Prefusion F protein IVX-121 Postfusion protein subunit Prefusion stabilized protein subunit VLP with multivalent display of vaccines vaccines stabilized prefusion proteins (e.g., DS-Ca
Slide 19: NIH published long-term immunogenicity data from Phase 1 DS-Cav1 study
NIH recently published long-term immunogenicity and full dose range data from the Phase 1 DS-Cav1 study • Study was conducted in younger adults (N=95) – Can provide a reference point for Phase 1 portion of IVX-121 study • Dose range 50, 150 and 500 mcg +/- alum – Transient dose effect at week 4, mar
Slide 20: IVX-121 potential to induce higher neutralizing antibody titers than DS-Cav1
IVX-121 has the potential to induce higher neutralizing antibody titers than the soluble prefusion DS-Cav1 antigen, which could lead to greater disease prevention RSV-primed mice Naïve non-human primates Neutralizing Antibody Titer Induction of Antigen-specific Neutralizing Antibody Titers after a S
Slide 21: IVX-121 Ph1/1b Trial Design in healthy adults and older adults
IVX-121 Ph1/1b Trial Design in healthy adults and healthy older adults PHASE 1B REVACCINATION PHASE 1 PHASE 1B Preliminary; subject to change • Healthy older adults 60 - 75 yrs • Subset of expanded Ph1b cohort • First-in-Human dose escalation • Healthy younger adults 18 - 45 yrs • 6 treatment groups
Slide 22: Icosavax has selected a prefusion stabilized F hMPV antigen for IVX-241
Icosavax has selected a prefusion stabilized F hMPV antigen for incorporation into IVX-241 • Similar to RSV, the critical hMPV F protein target undergoes a confirmational change upon fusing to the Postfusion F Protein Prefusion F Protein cell membrane – Prefusion structure likely needed to maintain
Slide 23: RSV and hMPV two-component VLPs can be combined without significant immune interference
Preliminary studies indicate RSV and hMPV two-component VLPs can be combined to generate a bivalent immunogen (IVX-A12) without significant immune interference RSV/A hMPV/A RSV/A hMPV/A • Study performed in cotton rats 14 14 • 1 ug VLP in monovalent groups; 1 ug of each VLP in 12 12 IVX-121 bivalent
Slide 24: IVX-A12 potential Ph1 and Ph2 trials in healthy older adults
IVX-A12 potential Ph 1 and 2 trials in healthy older adults Preliminary study designs, are subject to change PHASE 1 PHASE 2 FACTORIAL PHASE 2 DURATION • Objective: Safety and immunologic • Objective: Long-term safety and • Objective: Safety and immunogenicity of non-interference between VLPs in dur
Slide 25: Competitive landscape of RSV, hMPV and combination vaccines for older adults
Competitive landscape of RSV, hMPV and combination RSV/hMPV vaccines for older adults Preclinical Phase 1 Phase 2 Phase 3 Prefusion RSV-F+alum VLP RSV+hMPV GSK Prefusion RSV-F + ASO1 Subunit / Pfizer Prefusion RSV-F + alum Soluble Antigen Moderna* RSV-F Nucleic Acid Janssen Adenovirus (AdVac) RSV-F
Slide 26: RSV vaccine potential to be recommended by policy makers; combination may be preferred
A vaccine against RSV has the potential to be recommended by policy makers, which could drive rapid coverage and uptake; a combination RSV+ vaccine may be preferred by vaccinators Policy makers and payors: • Icosavax has completed an extensive primary and Anticipated recommendations for a RSV vaccin
Slide 27: SARS-CoV-2 Vaccine Candidate
SARS-CoV-2 Vaccine Candidate Icosavax, Inc. 27
Slide 28: IVX-411 utilizes the Icosavax VLP platform to display RBD antigen
IVX-411 utilizes the Icosavax VLP technology platform and is designed to display receptor binding protein (RBD) antigen for SARS-CoV-2 Spike glycoprotein RBD RBD fused to RBD nanoparticle vaccine • RBD critical functional “S-2P” Component A domain of spike protein responsible for interaction with AC
Slide 29: Ph 1/2 studies to demonstrate prime-boost and universal booster potential of IVX-411
Icosavax is conducting Ph 1/2 studies to demonstrate “prime-boost” and “universal booster” potential of IVX-411 PH 1/2 PART 1: PRIMARY IMMUNIZATION PH 1/2 PART 2: BOOST PREVIOUSLY ADDITIONAL CLINICAL PLANS WITH IVX-411 VACCINATED WITH IVX-411 Preliminary; subject to change • Candidate: IVX-411 • Exp
Slide 30: IVX-411 induced high neutralizing antibody titer against original strain and variants in mice
IVX-411 induced high neutralizing antibody titer against SARS-CoV-2 original strain and variants of concern in mice PNA Neutralizing Titer (B.1.351) PNA Neutralizing Titer (B.1) PNA Neutralizing Titer (B.1.351) PNA Neutralizing Titer (B.1) 5 10 5 10 4 4 10 10 B.1.351 B.1 PSEUDO- FOLD DROP SERA PSEUD
Slide 31: COVID-19 landscape is crowded, only a few VLPs in development
While the COVID-19 landscape is crowded, there are only a few VLPs in development COVID Clinical Landscape – September 2021 4 18 We believe VLP-based vaccines have the potential to show robust titers clinically - to date this 7 hypothesis has been supported by published Medicago eVLP Ph 2 data as we
Slide 32: Icosavax Recap
Icosavax Recap Icosavax, Inc. 32
Slide 33: Novel VLP technology with multiple near-term value inflection points
Novel VLP technology with multiple near-term value inflection points $209.3 million gross proceeds raised in July 2021 IPO ACHIEVED 1H 2022 PLANNED SUBSEQUENT KEY ANTICIPATED CANDIDATE INDICATION MILESTONES IN 2021 MILESTONES MILESTONES DP release; Plan to transition development to IVX-A12 CTA appro